PubRank

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Clinical Trial ID NCT02041533

PubWeight™ 32.45‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02041533

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2015 4.68
2 Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015 1.67
3 PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015 1.53
4 Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol 2015 1.45
5 Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 2015 1.21
6 Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep 2015 1.18
7 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
8 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
9 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol 2015 0.97
10 Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015 0.97
11 Checkpoint inhibitors in lung cancer: latest developments and clinical potential. Ther Adv Med Oncol 2016 0.96
12 PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 2016 0.95
13 Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med 2015 0.95
14 Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol 2016 0.89
15 New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2015 0.89
16 Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol 2015 0.87
17 Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol 2014 0.85
18 Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. Drugs Context 2015 0.84
19 Reflections on immune checkpoint inhibition in non-small cell lung cancer. Transl Lung Cancer Res 2014 0.81
20 The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist 2015 0.81
21 Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Transl Lung Cancer Res 2015 0.80
22 New targeted treatments for non-small-cell lung cancer - role of nivolumab. Biologics 2016 0.79
23 Promising targets and current clinical trials in metastatic squamous cell lung cancer. Front Oncol 2014 0.78
24 Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer. Transl Lung Cancer Res 2015 0.78
25 Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res 2014 0.78
26 Chemotherapy remains an essential element of personalized care for persons with lung cancers. Ann Oncol 2016 0.77
27 Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 2015 0.77
28 Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. Ann Transl Med 2016 0.77
29 Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets. Nat Rev Clin Oncol 2015 0.76
30 Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer? Transl Lung Cancer Res 2016 0.75
31 European Cancer Congress 2015. P T 2015 0.75
32 Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. Ann Oncol 2016 0.75
33 Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther 2016 0.75
Next 100